



US00PP33000P3

(12) **United States Plant Patent**
Lewis et al.

(10) **Patent No.:** **US PP33,000 P3**
(45) **Date of Patent:** **Apr. 27, 2021**

(54) **CANNABIS PLANT NAMED ‘OG CITRON’**

2014/0287068	A1	9/2014	Lewis et al.
2014/0298511	A1	10/2014	Lewis et al.
2015/0359188	A1	12/2015	Lewis et al.
2015/0366154	A1	12/2015	Lewis et al.
2016/0324091	A1	11/2016	Lewis et al.
2017/0202170	A1	7/2017	Lewis et al.
2018/0064055	A1	3/2018	Lewis et al.
2018/0143212	A1	5/2018	Lewis et al.
2018/0284145	A1	10/2018	Lewis et al.
2019/0183003	P1	6/2019	Lewis et al.
2019/0183004	P1	6/2019	Lewis et al.
2019/0183005	P1	6/2019	Lewis et al.
2019/0183006	P1	6/2019	Lewis et al.
2019/0183007	P1	6/2019	Lewis et al.
2019/0183008	P1	6/2019	Lewis et al.
2019/0183009	P1	6/2019	Lewis et al.
2019/0183010	P1	6/2019	Lewis et al.

(50) Latin Name: **Cannabis hybrid**
Varietal Denomination: **OG CITRON**

(71) Applicant: **Biotech Institute, LLC**, Westlake Village, CA (US)

(72) Inventors: **Mark Anthony Lewis**, Westlake Village, CA (US); **Steven Robert Haba**, Westlake Village, CA (US)

(73) Assignee: **Biotech Institute, LLC**, Westlake Village, CA (US)

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.

(21) Appl. No.: **16/501,446**

(22) Filed: **Apr. 17, 2019**

(65) **Prior Publication Data**

US 2019/0254213 P1 Aug. 15, 2019

Related U.S. Application Data

(63) Continuation of application No. 16/350,327, filed on Nov. 5, 2018, now Pat. No. Plant 31,917.

(60) Provisional application No. 62/596,561, filed on Dec. 8, 2017.

(51) **Int. Cl.**

A01H 5/02	(2018.01)
A01H 6/28	(2018.01)
A61K 36/185	(2006.01)

(52) **U.S. Cl.**

USPC	Plt./258
CPC	A01H 6/28 (2018.05); A61K 36/185 (2013.01)

(58) **Field of Classification Search**

USPC	Plt./258, 263.1
CPC ...	A01H 5/12; A01H 5/00; A01H 5/02; A01H 6/28; A61K 36/185

See application file for complete search history.

(56) **References Cited**

U.S. PATENT DOCUMENTS

9,095,554	B2	8/2015	Lewis et al.
9,370,164	B2	6/2016	Lewis et al.
PP27,475	P2	12/2016	Kubby
9,642,317	B2	5/2017	Lewis et al.

FOREIGN PATENT DOCUMENTS

WO	WO 2014/145490	A2	9/2014
WO	WO 2015/065544	A1	5/2015
WO	WO 2016/105514	A1	6/2016
WO	WO 2016/123160	A1	8/2016
WO	WO 2018/094359	A1	5/2018

OTHER PUBLICATIONS

Alchimia The effect of cold on *Cannabis* plants 2017, retrieved on Mar. 18, 2020, retrieved from the Internet at <https://www.alchimiaweb.com/blog/en/the-cold-during-a-cannabis-plant-crop/>, 13 pp. (Year: 2017).*

Grasscity Forums, "Lemon Crush", 2010, retrieved on May 1, 2019 from <https://forum.grasscity.com/threads/lemon-crush-weed.475046/>, 7 pages

Reddit, "Cake batter?," 2016, retrieved on Jun. 10, 2019, from https://www.reddit.com/r/CannabisExtracts/comments/4jcow1/cake_batter/, 5 pages.

Weed Connection, "#Cake Batter #OG," 2016, retrieved on Jun. 11, 2019, from <https://weedconnection.com/medz/link/cakebatterogkush.html>, 2 pages.

* cited by examiner

Primary Examiner — June Hwu

(74) Attorney, Agent, or Firm — Cooley LLP

(57) **ABSTRACT**

Disclosed herein are main terpenes of ‘OG CITRON’, which are linalool, limonene, myrcene, beta-caryophyllene, alpha-bisabolol, alpha-humulene, and beta-pinene. Also, the present invention provides the estimated concentration of the THC_{max}, CBD_{max} and CBG_{max}, about 9.90-12.66%, about 5.50-9.23%, and about 0.08-0.78%, respectively, at the time of assaying metabolites from flower samples of ‘OG CITRON’.

8 Drawing Sheets

CANNABIS PLANT NAMED 'OG CITRON'

Latin name of genus and species: *Cannabis* hybrid.
Variety denomination: 'OG CITRON'.

BACKGROUND OF THE INVENTION

The present invention relates to a new and distinct *Cannabis* cultivar designated as 'OG CITRON'.

This new cultivar is the result of controlled-crosses between proprietary cultivars made by the inventors. The new cultivar of 'OG CITRON' was asexually reproduced via a 'stem cutting' and 'cloning' method by the inventors at Salinas, Calif. Asexual clones from the original source have been tested in greenhouses, nurseries, and/or fields. The properties of each cultivar were found to be transmissible by such asexual reproduction. The cultivar is stable and reproduces true to type in successive generations of asexual reproduction.

TAXONOMY AND NOMENCLATURE

Cannabis, more commonly known as marijuana, is a genus of flowering plants that includes at least three species, *Cannabis sativa*, *Cannabis indica*, and *Cannabis ruderalis* as determined by plant phenotypes and secondary metabolite profiles. In practice however, *Cannabis* nomenclature is often used incorrectly or interchangeably. *Cannabis* literature can be found referring to all *Cannabis* varieties as "sativas" or all cannabinoid producing plants as "indicas". Indeed the promiscuous crosses of indoor *Cannabis* breeding programs have made it difficult to distinguish varieties, with most *Cannabis* being sold in the United States having features of both *sativa* and *indica* species.

Human cultivation history of *Cannabis* dates back 8,000 years (Schultes, R E., 1970, Random thoughts and queries on the botany of *Cannabis*. Pages 11-38 in: CRB Joyce, and S H Curry eds., THE BOTANY AND CHEMISTRY OF CANNABIS. J. & A. Churchill. London, England). Hemp cloth recovered in Europe dates back 6,000 years (Small, E, Beckstead, H D, and Chan, A, 1975, The evolution of cannabinoid phenotypes in *Cannabis*, ECONOMIC BOTANY 29(3):219-232). The written record of the pharmacologic properties of *Cannabis* goes back more than 4,000 years (Ti, H. 2737 BC. NEI JING SU WEN HUANG TI, Yellow Emperor's Classic on Internal Medicine; referred to without citation in Small et al. 1975 Supra).

The taxonomy and nomenclature of the highly variable genus *Cannabis* (Emboden, W A, 1974, ECONOMIC BOTANY 28(3):304-310; Small, E and Cronquist, A, 1976, TAXON 25(4):405-435; Small E and Cronquist, A, 1977, TAXON 26(1):110; Hillig, K W and Mahlberg, P G, 2004, American Journal of Botany 91(6):966-975), remains in question. This is in spite of the fact that its formal scientific name, '*Cannabis sativa* L.', assigned by Carolus Linnaeus (Linnaeus, C, 1753, SPECIES PLANTARUM, 2:1027, Salvius, Stockholm, Facsimile edition, 1957-1959, Ray Society, London, U.K.), is one of the oldest established names in botanical history and is still accepted to this day. Another species in the genus, '*Cannabis indica* Lam.' was formally named somewhat later (Lamarck, J B, 1785, ENCYCLOPEDIA METHODIQUE DE BOTANIQUE, 1(2):694-695), but is still very old in botanical history. In 1785, Jean-Baptiste Lamarck published a description of a second species of *Cannabis*, which he named *Cannabis indica*. Lamarck based his description of the newly named species on plant specimens collected in India. *C. indica* was

described as relatively short, conical, and densely branched, whereas *C. sativa* was described as tall and laxly branched (Schultes R. E. et al, 1974, Harvard University Botanical Museum Leaflets, 23:337-367). *C. indica* plants were also described as having short, broad leaflets whereas those of *C. sativa* were characterized as relatively long and narrow (Anderson L. C., 1980, Harvard University Botanical Museum Leaflets, 28: 61-69). *C. indica* plants conforming to Schultes' and Anderson's descriptions may have originated from the Hindu Kush mountain range. Because of the often harsh and variable (extremely cold winters, and warm summers) climate of those parts, *C. indica* is well-suited for cultivation in temperate climates.

Three other species names were proposed in the 1800s to distinguish plants with presumably different characteristics (*C. macrosperma* Stokes, *C. chinensis* Delile, *C. gigantea* Vilmorin), none of which are accepted today, although the epithet "*indica*" lives on as a subspecies of *C. sativa* ('*C. sativa* ssp. *indica* Lam.', Small and Cronquist 1976 Supra).

In the 20th century, two new names were added to the liturgy of proposed '*Cannabis* species: *C. ruderalis*' Janischewsky and a hybrid, x '*C. intersita*' Sojak. (Small, E, Jui, P Y, and Lefkovitch, L P, 1976, SYSTEMATIC BOTANY 1(1):67-84; Small and Cronquist 1976 Supra). Further, numerous names have been proposed for horticultural variants of '*Cannabis*' but as of 1976, "very few of these have been validly published as formal taxa under the International Code of Botanical Nomenclature" (Small and Cronquist 1976 Supra). Moreover, other recent work continues to focus on higher-order evolutionary relationships of the genus. *Cannabis* has been variously ascribed as belonging to mulberry family (Moraceae) (Engler, H G A, Ulmaceae, Moraceae and Urticaceae, pages 59-118 in: A. Engler and K. Prantl eds., 1889, DIE NATURLICHEN PFLANZENFAMILIEN 3(1). W. Engelmann, Leipzig, Germany; Judd, W S, Sanders, R W, and Donoghue, M J, 1994, HARVARD PAPERS IN BOTANY 5:1-51; Humphries, C J and Blackmore, S, A review of the classification of the Moraceae, pages 267-277 In: Crane and Blackmore 1989 id.); nettle family (Urticaceae) (Berg, C C, Systematics and phylogeny of the Urticales, pages 193-220, in: P. R. Crane and S. Blackmore eds., 1989, EVOLUTION, SYSTEMATIC, AND FOSSIL HISTORY OF THE HAMAMELIDAE, VOL. 2, HIGHER HAMAMELIDAE, Clarendon Press, Oxford, U.K.); and most recently in its own family with hops (Humulus), Cannabaceae, or hemp family (Sytsma, K J, et al, 2002, AMERICAN JOURNAL OF BOTANY 89(9):1531-1546). While the work of Small and Cronquist 1976 Supra, seemed to effectively confine the genus to a single species with 2 subspecies (*C. sativa* s., *C. s. indica*), each with two varieties (*C. s. s. var. sativa*, *C. s. s. var. spontanea*; *C. s. i. var. indica*, *C. s. i. var. kafirsitanica*) largely on the basis of chemotaxonomy and interfertility of all forms, more recent work (Sytsma et al. 2002 Supra), proposes a two-species concept, resurrecting the binomial *C. indica* Lam. Since Sytsma et al. (2002) provides no key for discriminating between the species, the dichotomous key of Small and Cronquist (1976), which accounts for all forms in nature, whether wild or domesticated, is preferred to classify the characteristics of the plants.

BRIEF SUMMARY OF THE INVENTION

This invention relates to a new and distinctive *Cannabis* cultivar designated as 'OG CITRON'.

The objective of the breeding program which produced novel plants disclosed herein was primarily to develop a

Cannabis cultivar with its unique blend of various cannabinoids and/or terpenes for (a) medicinal effects such as improving appetite and reducing nausea, vomiting and/or chronic pain, as well as neurological and cardiovascular effects, (b) psychoactive effects such as increased motivation and energetic behavior rather than indifference, passiveness and lethargy, and (c) recreational effects with enhanced enjoyment such as food and aroma.

As used herein, the term “cultivar” is used interchangeably with “variety”, “strain”, and/or “clone”.

Cannabis plants produce a unique family of terpenophenolic compounds. Cannabinoids, terpenoids, and other compounds are secreted by glandular trichomes that occur most abundantly on the floral calyxes and bracts of female plants. As a drug it usually comes in the form of dried flower buds (marijuana), resin (hashish), or various extracts collectively known as hashish oil. The *Cannabis* plant has at least 545 distinct compounds that span twenty chemical classes including cannabinoids, terpenes, terpenoids, amino acids, nitrogenous compounds, simple alcohols, aldehydes, ketones, esters, lactones, acids, fatty acids, steroids, non-cannabinoid phenols, pigments, flavonoids, vitamins, proteins, enzymes, glycoproteins, and hydrocarbons. Terpenes and/or cannabinoids, in particular, have shown great potential in terms of medicinal value.

Terpenes and/or cannabinoids have been shown to be largely responsible for beneficial effects of a *Cannabis* plant. In fact, each *Cannabis* plant has the varying concentrations of medically viable compounds depending on different strains (genotypes) and their resulting chemotypes. Even a small variation in terpene and/or cannabinoid concentration can cause noticeable differences in the entourage and/or synergistic effects of a *Cannabis* plant, which distinguishes one variety from another. Research shows that it relies heavily on the physiological effects produced by terpenes and/or cannabinoids.

Over one hundred different kinds of terpenes have been identified in *Cannabis* plants although not being as well-studied as cannabinoids, they are instrumental in giving rise to the physiological and psychoactive effects in *Cannabis*.

Terpenes are a large and diverse class of organic compounds, produced by a variety of plants. They are often strong smelling and thus may have had a protective function. Terpenes are an important component, not only influencing taste and smell of each *Cannabis* strain but also influencing its effects on the mind and body of a subject such as humans and animals. Terpenes are a classification of organic molecules that are found in a wide variety of plants and animals. These molecules are known for their characteristic scents and flavors. The varying terpene concentrations found in *Cannabis* plants directly influence the resulting taste and smell, as well as the observed effects. Non-limiting examples of types of terpenes include Hemiterpenes, Monoterpenes, Sesquiterpenes, Diterpenes, Sesterterpenes, Triterpenes, Sesquaterpenes, Tetraterpenes, Polyterpenes, and Norisoprenoids. The main terpenes found in *Cannabis* plants include, but are not limited to, myrcene, limonene, caryophyllene, pinene, terpinene, terpinolene, camphene, terpineol, phellandrene, carene, humulene, pulegone, sabinene, geraniol, linalool, fenchol, borneol, eucalyptol, and nerolidol.

Cannabinoids are the most studied group of the main physiologically active secondary metabolites in *Cannabis*. The classical cannabinoids are concentrated in a viscous resin produced in structures known as glandular trichomes. At least over one hundred different cannabinoids have been isolated from *Cannabis* plants. The main classes of cannabi-

noids from *Cannabis* include, but are not limited to tetrahydrocannabinol (THC), cannabidiol (CBD), cannabigerol (CBG), and cannabiol (CBN). Cannabinoid can be at least one of a group comprising tetrahydrocannabinol (THC), cannabidiol (CBD), cannabigerol (CBG), cannabiol (CBN), cannabichromene (CBC), cannabiodiol (CBDL), cannabicyclol (CBL), cannabivarin (CBV), tetrahydrocannabivarin (THCV), cannabidivarin (CBDV), cannabigerovarin (CBGV), cannabichromevarin (CBCV), cannabigerol monomethyl ether (CBGM), cannabielsoin (CBE), cannabicitran (CBT), cannabiol propyl variant (CBNV), cannabitrilol (CBO), and their acidic counterparts, such as tetrahydrocannabinolic acid (THCA), tetrahydrocannabivarinic acid (THCVA), cannabidivarinic acid (CBDVA), cannabidiolic acid (CBDA), cannabigerolic acid (CBGA) and cannabinerolic acid (CBNRA).

Most cannabinoids exist in two forms, as acids and in neutral (decarboxylated) forms. The acidic form of cannabinoids is designated by an “A” at the end of its acronym (i.e. THCA). The cannabinoids in their acidic forms (those ending in “-A”) can be converted to their non-acidic forms through a process called decarboxylation when the sample is heated. The phytocannabinoids are synthesized in the plant as acidic forms. While some decarboxylation does occur in the plant, it increases significantly post-harvest and the kinetics increase at high temperatures (Flores-Sanchez and Verpoorte, 2008, *Plant Cell Physiol.* 49(12): 1767-1782). The biologically active forms for human consumption are the neutral forms. Decarboxylation is usually achieved by thorough drying of the plant material followed by heating it, often by combustion, vaporization, heating, or baking in an oven. Unless otherwise noted, references to cannabinoids in a plant include both the acidic and decarboxylated versions (e.g., CBD and CBDA).

The molecules lose mass through the process of decarboxylation. In order to find the total theoretical active cannabinoids, the acid forms should be multiplied by 87.7%. For example, THCA can be converted to active THC using the formula: $THCA \times 0.877 = THC$. The maximum THC for the sample is: $THC_{max} = (THCA \times 0.877) + THC$. This method has been validated according to the principles of the International Conference on Harmonization. Similarly, CBDA can be converted to active CBD and the yield is determined using the yield formula: $CBDA \times 0.877 = CBD$. Also the maximum amount of CBD yielded, i.e. max CBD for the sample is: $CBD_{max} = (CBDA \times 0.877) + CBD$. Additionally, CBGA can be converted to active CBG by multiplying 87.8% to CBGA. Thus, the maximum amount of CBG is: $CBG_{max} = (CBGA \times 0.878) + CBG$.

The biologically active chemicals found in plants, phytochemicals, may affect the normal structure or function of the human body and in some cases treat disease. The mechanisms for the medicinal and psychoactive properties of a *Cannabis* plant, like any medicinal herb, produce the pharmacologic effects of its phytochemicals, and the key phytochemicals for a medical *Cannabis* plant are cannabinoids and terpenes.

Δ^9 -Tetrahydrocannabinol (THC) is a psychoactive cannabinoid responsible for many of the effects such as mild to moderate pain relief, relaxation, insomnia and appetite stimulation. THC has been demonstrated to have anti-depressant effects. The majority of strains range from about 12-21% THC with very potent and carefully prepared strains reaching even higher. While Δ^9 -Tetrahydrocannabinol (THC) is also implicated in the treatment of disease, the psychotropic activity of THC makes it undesirable for some patients and/or indications.

Tetrahydrocannabinol, THC, is the primary psychoactive and medicinal cannabinoid and is the result of the decarboxylation of tetrahydrocannabinolic acid (THC-A), its acidic precursor. THC-A, (6a,10a)-1-hydroxy-6,6,9-trimethyl-3-pentyl-6a,7,8,10a-tetrahydro-6h-benzochromene-2-carboxylic acid, is found in the trichomes of the plant and converted into THC, which actually exists in only minute quantities in the living plant, after harvest and drying.

Cannabidiol (CBD) is one of the principal cannabinoids found in a *Cannabis* plant and is largely considered to be the most medically significant. CBD occurs in many strains, at low levels, <1%. In some cases, CBD can be the dominant cannabinoid, as high as 15% by weight. CBD is non-psychoactive, meaning that unlike THC, CBD does not cause a noticeable "high". CBD has shown potential for its medical properties in the treatment of a wide variety of diseases and symptoms, including cancer, nausea, chronic pain, spasms, seizures/epilepsy, anxiety, psoriasis, Crohn's disease, rheumatoid arthritis, diabetes, schizophrenia, post-traumatic stress disorder (PTSD), alcoholism, strokes, multiple sclerosis, and cardiovascular disease. CBD also has been reported to act as a muscle relaxant, antibiotic, anti-inflammatory, and bone stimulant, as well as to improve blood circulation, cause drowsiness, and protect the nervous system. It can provide relief for chronic pain due to muscle spasticity, convulsions and inflammation, as well as effective relief from anxiety-related disorders. It can offer relief for patients with Multiple Sclerosis (MS), Fibromyalgia and Epilepsy. CBD has also been shown to inhibit cancer cell growth when injected into breast and brain tumors in combination with THC.

A *Cannabis* cultivar can be used to achieve the desire of patients to be treated with CBD without the adverse side-effects (e.g., psychoactivity) of THC.

Cannabichromene (CBC) is a rare, non-psychoactive cannabinoid, usually found at low levels (<1%) when present. It has been shown to have anti-depressant effects and to improve the pain-relieving effects of THC. Studies have demonstrated that CBC has sedative effects such as promoting relaxation.

Cannabidiol (CBD) and cannabichromene (CBC) are both non-psychoactive and end products of CBG metabolism, like THC, so that they can be used medically.

Cannabigerol (CBG) is a non-psychoactive cannabinoid. CBG-acid is the precursor to both THC-acid and CBD-acid in the plant usually found at low levels (<1%) when present. It has been demonstrated to have both pain relieving and inflammation reducing effects. CBG reduces intraocular pressure, associated with glaucoma. CBG has been shown to have antibiotic properties and to inhibit platelet aggregation, which slows the rate of blood clotting. While Cannabigerol (CBG), is not considered psychoactive, it is known to block the psychoactive effects of THC and is considered medically active in a variety of conditions. Its precursor, cannabigerolic acid, CBG-A, (E)-3-(3,7-Dimethyl-2,6-octadienyl)-2,4-dihydroxy-6-pentylbenzoic acid, is being studied medically.

Cannabinol (CBN) is an oxidative degradation product of THC. It may result from improper storage or curing and extensive processing, such as when making concentrates. It is usually formed when THC is exposed to UV light and oxygen over time. CBN has some psychoactive properties, less strength than THC. CBN is thought to enhance the dizziness and disorientation that users of *Cannabis* may experience. It may cause feelings of grogginess, and has been shown to reduce heart rate.

High potency *Cannabis* plants contain large quantities of specific terpenes as well as various assortments of other terpenes. For instance, a *Cannabis* plant may have a profile with either a high level of, a moderate amount of, or a small amount of various terpenes depending on its cultivar and environmental conditions.

Various cultivars of '*Cannabis*' species have been cultivated in an effort to create a cultivar best suited to meet the interest of inventors according to their own need. The particular plant disclosed herein was discovered in the area where the inventors were intentionally cross-pollinating and cultivating plants described below using standard Mendelian breeding procedures well known to those of ordinary skill in the art. This resulted in the progenies of the inventors' crosses.

The progenies resulting from any selection stage of either the crossing, selfing or backcrossing versions of the breeding regimes of the present invention were asexually reproduced to fix and maintain the desirable THC content, CBs content, terpenes content, the aroma and flavor(s) typical of the desired class, and the other desirable phenotypic and/or genotypic characteristics. The resultant selected *Cannabis* cultivar is designated as 'OG CITRON' disclosed herein.

The inventors reproduced progenies asexually by stem cutting and cloning. This is the origin of this remarkable new cultivar. The plant has been and continues to be asexually reproduced by stem cutting and cloning at the inventors' greenhouses, nurseries and/or fields in Salinas, Calif., Oakland, Calif., and/or Washington, D.C.

The following are the most outstanding and distinguishing chemical characteristics of this new cultivar when grown under normal conditions in Salinas, Calif. Chemical analyses of the new *Cannabis* variety and the check variety (or the parental varieties) disclosed herein were performed using standard chemical separation techniques well known to those skilled in the art. Samples for assaying were obtained from flower tissues of the *Cannabis* plant disclosed herein. Cannabinoid composition of this cultivar can be determined by assaying the concentration of at least one cannabinoid in a subset (e.g., sample) of the harvested product.

Table 1 includes detailed information of the *Cannabis* plant named 'OG CITRON' including the concentration ranges of terpenes and cannabinoids as tested on flowers at least twelve different times. The *Cannabis* plant has been tested in a laboratory setting and/or facility to determine cannabinoids and terpenes concentrations in the *Cannabis* plant named 'OG CITRON' according to the procedures provided in Giese et al. (Journal of AOAC International (2015) 98(6):1503-1522). High throughput homogenization (HTH) of typical inflorescences as a single sample preparation method for the analysis of both terpenoids and cannabinoids. HPLC-UV assay was used for HTH of cannabinoids, while GC-flame ionization detector (FID) was used for HTH of terpenes.

- 1) The main terpenes found in 'OG CITRON' are linalool, limonene, myrcene, beta-caryophyllene, alpha-bisabolol, alpha-humulene, and beta-pinene; and
- 2) The estimated concentration of the total THC_{max}, CBD_{max}, and CBG_{max} is about 9.90-12.66%, about 5.50-9.23%, and about 0.08-0.78%, respectively, at the time of assaying metabolites from flower samples of 'OG CITRON'.

Terpene and cannabinoid profiles of 'OG CITRON' demonstrate that 'OG CITRON' has a phenotypically unique profile, particularly insofar as to the level of terpenes and cannabinoids. This data is presented in a tabular form in Table 1.

TABLE 1

Ranges of Active Cannabinoids and Terpenes					
Ranges of Active Cannabinoids (% by weight)					
Max THC	9.90-12.66%	Max CBD	5.50-9.23%	Max CBG	0.08-0.78%
Ranges of Terpenes (% by weight)					
thujene	0.00%	gamma-terpinene	0.00%	hexyl hexanoate	0.00-0.03%
alpha-pinene	0.02-0.05%	linalool oxide	0.00-0.02%	octyl butyrate	0.00%
camphene	0.00-0.02%	terpinolene	0.00-0.01%	beta-caryophyllene	0.21-0.32%
sabinene	0.00%	fenchone	0.00%	alpha-humulene	0.09-0.14%
beta-pinene	0.05-0.10%	linalool	0.24-0.71%	cis-nerolidol	0.00%
myrcene	0.11-0.47%	fenchol	0.02-0.07%	trans-nerolidol	0.00%
alpha-phellandrene	0.00%	—	—	caryophyllene oxide	0.01-0.04%
carene	0.00%	camphor	0.00%	alpha-bisabolol	0.00-0.16%
alpha-terpinene	0.00%	isoborneol	0.00%	nerol	0.00%
limonene	0.26-0.64%	(-)-borneol	0.00-0.02%	geraniol	0.00%
beta-phellandrene	0.00%	menthol	0.00%	geranyl-acetate	0.00%
cineole	0.00%	hexyl butyrate	0.00%	methyl-eugenol	0.00%
cis-ocimene	0.00%	alpha-terpineol	0.00-0.07%	Total Terpenes	1.67-2.57%
trans-ocimene	0.00%	citronellol	0.00%	—	—

The *Cannabis* plant named 'OG CITRON' has a complement of terpenes, including but not limited to, relatively high levels of linalool, limonene, myrcene, beta-caryophyllene, alpha-bisabolol, alpha-humulene, and beta-pinene compared to other terpene compounds. This unique combination of differently concentrated terpenes further distinguishes 'OG CITRON' from other varieties in its odor, its medical qualities, and its effects on mood and mentation.

Asexual Reproduction

Asexual reproduction, also known as "cloning", is a process well known to those of ordinary skill in the art of *Cannabis* production and breeding and includes the following steps.

The *Cannabis* cultivar disclosed herein is asexually propagated via taking cuttings of shoots and putting them in rock wool cubes. These cubes are presoaked with pH-adjusted water and kept warm (-80° F.). Full trays are covered, left under 18 hours of light and allowed to root (7-14 days). Upon root onset, the plantlets are transplanted into rigid 1 gallon containers filled with a proprietary soil mix A and remain in 18 hours of daylight for another 14-21 days. Once root-bound, plants are transplanted into rigid 3 gallon containers filled with proprietary soil mix B. Immediately, the light cycle is altered to 12/12 and flower initiating begins. The plants remain in 12/12 lighting until harvesting. They undergo a proprietary nutrient regimen and grow as undisturbed as possible for 60-70 days depending on chemotype analysis.

All sun leaves are removed and the plant is dismantled to result in approximately 12" branches covered in inflorescences and trichomes. The goal in harvesting is to actually harvest trichome heads but not 'buds'. Thus, great care is taken not to disturb the trichome heads and as much of the

plant remains intact as possible to promote even and slow drying. Slow drying is followed by a one to two months curing process.

Observation of the all female progenies of the original plant has demonstrated that this new and distinct cultivar has fulfilled the objectives and that its distinctive characteristics are firmly fixed and hold true from generation to generation vegetatively propagated from the original plant.

Under careful observation, the unique characteristics of the new cultivar have been uniform, stable and reproduced true to type in successive generations of asexual reproduction.

DESCRIPTION OF THE DRAWINGS

The accompanying color photographs depict characteristics of the new 'OG CITRON' plants as nearly true as possible to make color reproductions. The overall appearance of the 'OG CITRON' plants in photographs is shown in colors that may differ slightly from the color values described in the detailed botanical description.

FIG. 1 shows an overall view of the 'OG CITRON' plant from the side.

FIG. 2A shows a close view of a single leaf of the check variety BLK03 plant.

FIG. 2B shows a close view of a single leaf of the new variety 'OG CITRON' plant.

FIG. 3A shows top parts (including inflorescence) of the BLK03 plant from the side.

FIG. 3B shows top parts (including inflorescence) of the 'OG CITRON' plant from the side.

FIG. 4 shows a close view of flowers of the 'OG CITRON' plant at the mid to late flowering stage.

FIG. 5 shows another close view of flowers of the 'OG CITRON' plant at the mid to late flowering stage.

FIG. 6 shows a reproductive part of a sample *Cannabis* plant, indicating position/location of a flower, a bract and a stipule in the plant. The sample *Cannabis* plant in FIG. 6 is not the claimed 'OG CITRON' plant.

DETAILED BOTANICAL DESCRIPTION

'OG CITRON' has not been observed under all possible environmental conditions, and the phenotype may vary significantly with variations in environment. The following observations, measurements, and comparisons describe this plant as grown at Salinas, Calif., when grown in the greenhouse, nursery or field, unless otherwise noted.

Plants for the botanical measurements in the present application are annual plants. In the following description, the color determination is in accordance with The Royal Horticultural Society Colour Chart, 2007 Edition, except where general color terms of ordinary dictionary significance are used.

The *Cannabis* plant disclosed herein was derived from female and male parents that are internally designated as below.

The internal GNBR Code of the *Cannabis* plant named 'OG CITRON' is S8.08.34, also known as SLV08.P38.BX.08.34. The internal GNBR Breeding Code of the *Cannabis* plant named 'OG CITRON' is (S08)x (P38.BX.08).34. The additional number '.34' was only assigned to the 34th individual plant (i.e. 'OG CITRON') selected from progenies of the cross event between pollen acceptor (S08) and pollen donor (P38.BX.08). 'OG CITRON' is a fertile hybrid derived from a controlled-cross between two proprietary cultivars: (i) SLV08 (pollen accep-

tor; female parent), also known as S08 or S8, and (ii) P38.BX.08 (pollen donor; male parent), also known as 08. The initial cross between two parental cultivars was made in September 2015. The primary phenotypic criteria used to select the new and distinct *Cannabis* cultivar disclosed herein is as follows: structure score, nose/organoleptic testing, mold susceptibility/resistance, and insect susceptibility/resistance. Also, the chemotypic characteristics described in Table 1 were used to select the new and distinct *Cannabis* cultivar disclosed herein. The first asexual propagation of ‘OG CITRON’ occurred on Apr. 30, 2016 in Salinas, Calif.

The following traits in combination further distinguish the *Cannabis* cultivar ‘OG CITRON’ from the check variety ‘BLK03’, which is set as a standard for phenotypic comparison. Tables 2 to 6 present phenotypic traits and/or characteristics of ‘OG CITRON’ compared to the check variety ‘BLK03’ as follows. Unless otherwise indicated, all plants were raised together and evaluated when 90 days old (i.e., 23 days in vegetative stage, 15 days in clonal propagation stage, and 52 days in flowering times).

TABLE 2

General Characteristics		
Characteristics	New Variety	Check Variety (BLK03)
Plant life forms	An herbaceous plant (herb)	An herbaceous plant (herb)
Plant growth habit	An upright, tap-rooted annual plant; forming fibrous roots when asexually propagated	An upright, tap-rooted annual plant; forming fibrous roots when asexually propagated
Plant origin	A controlled-cross between pollen acceptor (SLV08) and (P38.BX.08)	A controlled-cross between pollen acceptor (GLD13) and pollen donor (BSIA)
Plant propagation ease	Asexually propagated by stem cuttings and cloning	Asexually propagated by stem cuttings and cloning
Height	1.50-2.30 m	0.50-2.50 m
Width	89.0 cm	119.5 cm
Plant vigor	High	Medium
Time to Harvest (Seed to Harvest)	7-8 weeks; as early as 50 days	8 weeks
Resistance to pests or diseases	Resistant to pests as follows; (1) Two-spotted spider mite (<i>Tetranychus urticae</i> (Koch)); (2) Aphids species such as: Cannabis Aphids (<i>Phorodon cannabidis</i>), Green Peach Aphid (<i>Myzus persicae</i> (Sulzer)), Foxglove Aphid (<i>Aulacorthum solani</i>), Peach Aphid (<i>Macrosiphum euphorbiae</i>), Black Bean Aphid (<i>Aphis fabae</i>); (3) Whitefly (<i>Trialeurodes vaporariorum</i>); (4) Lepidoptera species such as: Armyworm (<i>Spodoptera frugiperda</i>), Cabbage Whites (<i>Pieris rapae</i>), Painted Lady (Vanessa cardui), <i>Lepidoptera</i> sp.	Not Resistant to pests as follows; (1) Two spotted spider mite (<i>Tetranychus urticae</i> (Koch)); (2) Aphids species such as: Cannabis Aphids (<i>Phorodon cannabidis</i>), Green Peach Aphid (<i>Myzus persicae</i> (Sulzer)), Foxglove Aphid (<i>Aulacorthum solani</i>), Peach Aphid (<i>Macrosiphum euphorbiae</i>), Black Bean Aphid (<i>Aphis fabae</i>); (3) Whitefly (<i>Trialeurodes vaporariorum</i>); (4) Lepidoptera species such as: Armyworm (<i>Spodoptera frugiperda</i>), Cabbage Whites (<i>Pieris rapae</i>), Painted Lady (Vanessa cardui)

TABLE 2-continued

General Characteristics		
Characteristics	New Variety	Check Variety (BLK03)
	Resistant to diseases as follows; Powdery Mildew (<i>Podosphaera xanthii</i>)	cardui), <i>Lepidoptera</i> sp. Not resistant to diseases as follows; Botrytis/ Flower Rot (<i>Botrytis cinerea</i>) and Powdery Mildew (<i>Podosphaera xanthii</i>)
Genetically-modified organism	NO	NO

TABLE 3

Leaf/Foliage		
Characteristics	New Variety	Check Variety (BLK03)
Leaf arrangement	Alternate	Alternate
Leaf shape	Palmately compound	Palmately compound
Leaf structure	Linear-lanceolate leaflet blades with glandular hairs	Linear-lanceolate leaflet blades with glandular hairs
Leaf margins	Dentate, coarsely serrated, and the teeth point away from the tip	Dentate, coarsely serrated, and the teeth point away from the tip
Leaf hairs	Present and abundant on both upper and lower surfaces	Present on both upper and lower surfaces
Leaf length with petiole at maturity	40.20 cm	16.60 cm
Leaf width at maturity	9.3-15.9 cm	10.7 cm
Petiole length at maturity	17.10 cm	6.50 cm
Petiole color (RHS No.)	149A	140C
Intensity of petiole anthocyanin	Very weak	Medium (vegetative stage); very strong (late flowering stage)
Stipule length at maturity	0.70 cm	0.70 cm
Stipule shape	Bulbous	Elliptical
Stipule color (RHS No.)	134A	149B
No. of leaflets	5-7	5-7
Middle largest (longest) leaflet length	23.50 cm	9.80 cm
Middle largest (longest) leaflet width	4.70 cm	2.3 cm
Middle largest (longest) leaflet length/width ratio	23.5:4.7	9.8:2.3
No. teeth of middle leaflet (average)	40	25
Leaf (upper side) color (RHS No.)	132B	132A
Leaf (lower side) color (RHS No.)	141D	134D

11

TABLE 3-continued

Leaf/Foliage		
Characteristics	New Variety	Check Variety (BLK03)
Leaf glossiness	Medium at the upper leaf surface	Strong at the upper leaf surface
Vein/midrib shape	Obliquely continuous throughout leaflet	Obliquely continuous throughout leaflet
Vein/midrib color (RHS No.)	150B	144C
Aroma	Euphoric to Chemical/Ambrosial	Spicy

TABLE 4

Stem		
Characteristics	New Variety	Check Variety (BLK03)
Stem shape	Hollow and large	Hollow, ribbed, textured
Stem diameter at base	3.40 cm	2.80 cm
Stem color (RHS No.)	149D	N144D
Depth of main stem ribs/grooves	Shallow	Absent
Internode length	9.9-17.3 cm	2.4-4.9 cm

TABLE 5

Inflorescence (Female/Pistillate Flowers)		
Characteristics	New Variety	Check Variety (BLK03)
Flowering (blooming) habit	Cymes	Cymes
Proportion of female plants	100% pistillate	100% pistillate
Inflorescence position	Even	Even
Flower arrangement	Cymose (Inflorescences are very compact, and therefore bracts overlap within each cluster of flowers. Thus, the flowers are overlapping within each node)	Cymose (terminal bud matures, while lateral flowers mature thereafter)
Number of flowers per plant	25-50	80-120
Flower shape	Calcarate-urceolate	Calcarate-urceolate
Flower (individual pistillate) length	0.61 cm	0.70 cm
Flower (compound cyme) diameter	9.70 cm	3.80 cm
Corolla shape	No defined corolla	No defined corolla
Corolla Color (RHS No.)	N/A	N/A
Bract shape	Urceolate	Urceolate
Bract size	0.8-2.0 cm (high density of trichomes)	0.2-0.8 cm
Bract color (RHS No.)	130A	N134C
Calyx shape	No defined calyx	No defined calyx
Calyx color (RHS No.)	N/A	N/A
Stigma shape	Linear	Acute
Stigma length	0.1-0.4 mm	2.20 mm
Stigma color (RHS No.)	30A	159D

12

TABLE 5-continued

Inflorescence (Female/Pistillate Flowers)		
Characteristics	New Variety	Check Variety (BLK03)
Trichome shape	Capitate-stalked glandular	Capitate-stalked glandular
Trichome color (RHS No.)	157A at day 55 in flowering (before harvest)	157A at day 40 in flowering
Other types of trichomes	Capitate sessile trichomes are present on the upper and lower surfaces on leaves of plants, as well as being noticed in the flowers (color: 157A at day 55 in flowering). During later flowering, i.e. day 60 to day 70 in flowering, the capitate stalked trichomes are present (color: N30B).	Capitate sessile trichomes are present on the leaves of plants, as well as being noticed in the flowers (color: 157A at day 40 in flowering). During later flowering, i.e. day 48 to day 60 in flowering, capitate stalked trichomes are present (color: N30B). Bulbous and non-glandular trichomes are also present and most noticeable on the petioles, stems, and leaves (color: 157A). Oblong
Terminal bud shape	Urceolate	
Terminal bud color (RHS No.)	127B	203C
Pedicel	Absent	Absent
Staminate shape	No staminate flowers produced naturally; however, male flower (staminate) can be induced with chemical compounds (such as silver nitrate and silver thiosulphate anionic complex).	No staminate flowers produced naturally; however, male flower (staminate) can be induced with chemical compounds (such as silver nitrate and silverthiosulphate anionic complex).
Pollen description	Absent	Absent
Seed shape	Striped	Smooth and globular
Seed size (Diameter)	2.80-3.20 mm	1.80-2.30 mm
Marbling of seed	Weak to absent	Absent (non-existent)
Petal description	Apetalous	Apetalous
Max THC content	About 9.90-12.66%	About 18.88-19.37%
Max CBD content	About 5.50-9.23%	0.00%
Max CBG content	About 0.08-0.78%	About 0.84-0.91%
N/A: Not available		

TABLE 6

Other Characteristics		
Characteristics	New Variety	Check Variety (BLK03)
Time period and condition of flowering/blooming	7-9 weeks	7-9 weeks
Hardiness of plant	Hardy to 25° F-ambient temperature	Hardy to 25° F-ambient temperature
Breaking action	Flexible, resistant to breakage	Strong, non-flexible
Rooting rate after cutting/cloning	99%-vigorous	70%-moderate
Types of Cutting for Cloning	Stem	Stem

TABLE 6-continued

Other Characteristics		
Characteristics	New Variety	Check Variety (BLK03)
Shipping quality	Good	Moderate
Storage life	Medium (3-6 months with minor changes in physical appearance and/or smell/taste)	Medium (2-6 months with minor changes in physical appearance and/or smell/taste)
Market use	Medicinal	n/a

In general, 'OG CITRON' is larger in width and height than both parents, pollen acceptor (S08) and pollen donor (P38.BX.08). 'OG CITRON' is more robust in terms of growing performance, time to rooted clones, and time to flower maturity. As 'OG CITRON' has greater resistance to pests and disease (specifically to powdery mildew), it yields higher than both parents. Since 'OG CITRON' has stronger branches and thicker stems with greater flexibility than both parents, its main and lateral branches give 'OG CITRON' ability to produce higher yields under different/variable growing conditions. The flowers of 'OG CITRON' are larger in width and length than both parents. 'OG CITRON' clearly demonstrates hybrid vigor, and outperforms both parents overall. Chemically, 'OG CITRON' has a higher cannabinoid content with a high THC:CBD ratio as well as a higher terpene content than either parent. Also, 'OG CITRON' has unique combination of parental terpenes.

When 'OG CITRON' is compared to the check variety 'BLK03', 'OG CITRON' is narrower in width than 'BLK03' and has higher plant vigor than 'BLK03'. 'OG CITRON' has longer and wider leaves than 'BLK03' in terms of whole leaf length including petioles. Also, 'OG CITRON' has longer and wider leaflets than 'BLK03' when comparing the middle largest leaflet. 'OG CITRON' has more than twice longer

petioles in average than 'BLK03' at maturity, while it has about the same stipule size to 'BLK03'. Regarding the average stem diameter at base, 'OG CITRON' is longer than 'BLK03', and the internode length of 'OG CITRON' is also longer than that of 'BLK03'. When comparing the compound cyme diameter, 'OG CITRON' is longer than 'BLK03', while individual pistillate flowers of 'OG CITRON' are shorter than that of 'BLK03' in length. 'OG CITRON' has longer bracts than 'BLK03', while having shorter stigma. With respect to aroma, 'OG CITRON' has an ambrosial smell, while 'BLK03' has a generally spicy smell.


When 'OG CITRON' is compared to the known *Cannabis* plant named 'ECUADORIAN SATIVA' (U.S. Plant Pat. No. 27,475), there are several distinctive characteristics. For example, the overall form of 'OG CITRON' plant is taller in height and wider across at the widest point than 'ECUADORIAN SATIVA' plant. 'OG CITRON' plant has longer leaves including petioles, longer and wider middle leaflets, and longer petioles at maturity than 'ECUADORIAN SATIVA' plant. Regarding stem diameter at base, 'OG CITRON' plant is longer than 'ECUADORIAN SATIVA' plant. When comparing individual pistillate flower length, 'OG CITRON' flowers are longer than 'ECUADORIAN SATIVA' flowers. While the aroma of 'ECUADORIAN SATIVA' is strongly mephitic with hints of limonene, 'OG CITRON' has an ambrosial smell. When comparing total THC content between 'OG CITRON' and 'ECUADORIAN SATIVA', the total THC content of 'OG CITRON' is about 9.90-12.66%, while 'ECUADORIAN SATIVA' accumulates 12.45% total THC.

The invention claimed is:

1. A new and distinct cultivar of *Cannabis* plant named 'OG CITRON' substantially as shown and described herein.

* * * * *

FIG. 1



OG CITRON

FIG. 2A



BLK03

FIG. 2B



OG CITRON

FIG. 3A




BLK03

FIG. 3B



OG CITRON

FIG. 4



OG CITRON

FIG. 5



OG CITRON

FIG. 6

